JSC Grindeks informs that it has received approval from the governmentagency “Investment and Development Agency of Latvia” of allocation ofthe co-financing from the European Regional Development Fund for theconstruction of UDCA (ursodeoxycholic acid) manufacturing unit.Allocated amount of co-financing is 2.8 million lats.

About JSC Grindeks
Grindeks is the leading pharmaceutical company in the Baltic States. The main directions of its operation are research, development, manufacturing and sales of original products, as well as generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, psychotropic and anti-cancer therapeutic groups of medications.

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia; as well as representatives and representative offices in 14 countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, as well as Japan and USA. The shares of JSC Grindeks are listed in the Official List of “Nasdaq OMX Riga”.

Further information:
Laila Kļaviņa
Head of the Communications Department
JSC Grindeks
E-mail: laila.klavina@grindeks.lv
Phones: +371 67083370, +371 29256012